Hospital Pharmacy Europe - Neurology,

Click here

Tuesday 18 June 2013 Register Login

You are here:

Suppliers Guide

New neurology product

Complete an online survey about new products for stroke prevention and receive €225. Click here

LATEST ISSUE

Medication safety, improving patient outcomes, ‘smart’ pump implementation, monitoring of cleanrooms, aclidium bromide in the treatment of COPD, managing pain in renal impairment, labelling, cardiovascular disease risk management, RTU/RTA injections, preventing ischaemic stroke, topical anaesthetics in dermatology, High 5s

Pharmacy Zone: Neurology

Magazine	Sponsored content
News	Video

Page:

1

Tue 11 Jun

Switching to Novartis drug Gilenya
Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in...

Fri 7 Jun

New data shows Gilenya benefited multiple sclerosis
New data will be presented at the 23rd meeting of the European Neurological Society (ENS) that show how Novartis' Gilenya®...

Wed 29 May

World MS Day
Today, 29th May, 2013, Novartis joins the global multiple sclerosis (MS) community in celebration of World MS Day by launching a...

Tue 21 May

Molecular trigger for Alzheimer’s disease
For the first time, scientists at Cambridge’s Department of Chemistry have been able to map in detail the pathway that...

Mon 13 May

Accord Healthcare case successfully resolved
Accord Healthcare Ltd. has successfully resolved the case against AstraZeneca relating to the validity of the patent covering...

Fri 12 Apr

New neurology product
Hospital Pharmacy Europe is assisting with a survey on messaging for a new neurology product.

Wed 10 Apr

GW Pharmaceuticals announces Sativex® rescheduled in the UK
GW Pharmaceuticals, the biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from...

Wed 10 Apr

Lundbeck announces positive results for Brintellix™
H. Lundbeck A/S (Lundbeck) has announced positive results for the REVIVE study, a double-blind randomised study of...

Wed 10 Apr

New data on Selincro
H. Lundbeck A/S (Lundbeck) has announced the results of the revised analysis of the Phase III programme that formed the basis for...

Mon 8 Apr

Sativex® rescheduled by the Home Office
Bayer Healthcare, has announced that the UK Home Office, after advice from the Advisory Council on the Misuse of Drugs’...

Tue 26 Mar

Novartis confirms growing Gilenya® clinical experience
Latest global patient-use data show that Gilenya® (fingolimod) has been used to treat more than 63,000 patients in clinical...

Thu 21 Mar

Biotie presents Tozadenant Phase 2b data
Biotie has announced that full data from a Phase 2b study evaluating tozadenant (SYN115) in Parkinson's disease (PD) patients...

Thu 21 Mar

Orion Phase II data Alzheimer's disease drug
A novel drug (ORM-12741) developed by Orion Corporation could improve cognitive and behavioural symptoms in patients with...

Wed 20 Mar

Unmet medical need of multiple sclerosis
New data will be presented at the 65th annual meeting of the American Academy of Neurology (AAN) that show continued innovation...

Wed 13 Mar

Collaboration agreement in cognitive disorders
Orion Corporation ('Orion') and Gedeon Richter Plc. ('Richter') has announced that the two companies have entered into a...

Tue 29 Jan

TARGAXAN® 550 launched in the UK
Norgine Pharmaceuticals Limited and Alfa Wassermann are pleased to announce the launch of TARGAXAN® 550 in the UK - the only...

Mon 7 Jan

FDA approval of Rebif Rebidose
EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, and Pfizer Inc. announced today that the US Food and Drug...

Thu 13 Dec
2012

EISAI and UCL form major drug discovery alliance
UCL and the Japanese pharmaceutical company, Eisai have announced the agreement to establish a major drug discovery and...

Thu 13 Dec
2012

FDA accepts Takeda and Lundbeck’s filing for review of Brintellix
H. Lundbeck A/S (Lundbeck) has announced that the US Food and Drug Administration (FDA) has accepted the submission of a New Drug...

Fri 23 Nov
2012

Benefits of buccal midazolam in paediatric patients
Buccolam is the first and only licensed midazolam oromucosal solution in the EU presented in age-specific, single-use, prefilled...

Page:

1

Web design, hosting and programming by ModeZero